Skyrizi approved for psoriatic arthritis

(HealthDay)—The U.S. Food and Drug Administration has expanded the approval of Skyrizi (risankizumab-rzaa) to treatment of adults with active psoriatic arthritis, the manufacturer announced Friday.

Diseases, Conditions, Syndromes

Antibody combo prevents infection from SARS-CoV-2 exposure

(HealthDay)—For household contacts of infected persons, subcutaneous REGEN-COV, a combination of the monoclonal antibodies casirivimab and imdevimab, prevents symptomatic and asymptomatic severe acute respiratory syndrome ...


Gilead, Merck team up to develop long-acting HIV drug

American pharmaceutical companies Gilead and Merck announced Monday they have partnered to develop a new HIV therapy that could see daily medications replaced by a treatment that can be taken at longer intervals.


Novel immunotherapy approach to treat cat allergy

Researchers from the Department of Infection and Immunity of the Luxembourg Institute of Health (LIH) brought forward the potential of high doses of a specific adjuvant molecule, namely CpG oligonucleotide, in successfully ...

Diseases, Conditions, Syndromes

Team assessing if dual-antibody injection prevents COVID-19 illness

A combination antibody treatment for preventing COVID-19 illness in individuals who have had sustained exposure to someone with the virus is being studied by researchers at The University of Texas Health Science Center at ...


High-dose erythropoietin no benefit for extreme preemies

(HealthDay)—For extremely preterm infants, high-dose erythropoietin treatment from 24 hours after birth does not result in a reduced risk for severe neurodevelopmental impairment or death at age 2 years, according to a ...

page 1 from 2